Introduction to Peritoneal Rhabdomyosarcoma

Primary peritoneal rhabdomyosarcoma management is a critical area of concern in pediatric oncology due to the tumor's aggressive nature. This rare soft tissue malignancy often presents a diagnostic and therapeutic challenge for clinicians. Consequently, understanding the risks of surgical handling and rapid recurrence is vital for improving patient outcomes. Furthermore, recent case reports highlight that iatrogenic seeding during surgery might accelerate peritoneal spread, making early multimodal intervention essential.

Case Presentation: A Pediatric Diagnostic Challenge

A 6-year-old girl presented with a one-month history of lower abdominal swelling in Northern Ethiopia. Initially, clinicians used abdominopelvic ultrasound and computed tomography (CT) scans to evaluate the patient. These imaging modalities revealed a well-defined, 8-cm pelvic solid mass situated anterior to the uterus and bladder. Subsequently, the surgical team performed an exploratory laparotomy. During the procedure, they discovered a mass attached to the lower abdominal wall and anterior pelvic peritoneum. Notably, surgeons achieved what appeared to be a complete resection of the lesion.

Diagnosis and Rapid Recurrence

Following the surgery, histopathologic examination and immunohistochemistry (IHC) provided definitive answers. The tissue tested positive for desmin and myogenin, confirming a diagnosis of embryonal rhabdomyosarcoma. However, the clinical course took a tragic turn just five weeks postoperatively. The patient returned to the hospital with multiple malignant depositions across the peritoneum. Although the medical team immediately initiated systemic chemotherapy, the patient died before she could receive the second cycle. This rapid progression underscores the extreme virulence of this specific cancer subtype.

Optimizing Peritoneal Rhabdomyosarcoma Management Strategies

Refining peritoneal rhabdomyosarcoma management requires a shift toward preventive surgical techniques and early systemic therapy. Expert surgeons emphasize that handling the tumor with extreme care is necessary to avoid iatrogenic seeding. Additionally, evidence suggests that aggressive cytoreduction combined with hyperthermic intraperitoneal chemotherapy (HIPEC) might benefit a subset of patients. Therefore, multidisciplinary teams must prioritize early chemotherapy and radiation to control microscopic disease. Overall, this case serves as a stark reminder that even a macroscopically complete resection may not suffice without robust adjuvant support.

Key Lessons for Clinicians

Pediatric oncologists and surgeons should maintain a high index of suspicion when encountering pelvic masses in children. Specifically, the risk of rapid peritoneal recurrence suggests that surgical intervention alone is rarely curative for rhabdomyosarcoma. Furthermore, clinicians must ensure that IHC markers like desmin and myogenin are readily available to confirm the diagnosis. By integrating these lessons, the medical community can better navigate the complexities of this rare malignancy.

Frequently Asked Questions

What is the typical prognosis for primary peritoneal rhabdomyosarcoma?

The prognosis for this condition is generally poor due to its aggressive nature and tendency for early recurrence. Survival often depends on early diagnosis and the successful implementation of multimodal therapy including surgery, chemotherapy, and radiation.

How can surgical seeding be prevented in rhabdomyosarcoma cases?

Surgeons can minimize the risk of seeding by utilizing meticulous "no-touch" techniques and ensuring that the tumor capsule remains intact. Additionally, many experts recommend considering neoadjuvant chemotherapy to shrink the tumor before attempting a full resection.

What diagnostic markers are used for embryonal rhabdomyosarcoma?

Pathologists primarily rely on immunohistochemistry markers such as desmin, myogenin, and MyoD1. These markers are highly specific for muscle differentiation and help distinguish rhabdomyosarcoma from other small blue round cell tumors.

References

Gebreslase MN et al. Primary peritoneal embryonal rhabdomyosarcoma in a 6-year-old girl with rapid post-surgical peritoneal recurrence possibly due to surgical tumor seeding: a case report and review of the literature. J Med Case Rep. 2026 Feb 04. doi: 10.1186/s13256-026-05862-x. PMID: 41639885.

Kazi M, Qureshi SS. Primary Peritoneal Rhabdomyosarcomatosis in a 2-Year-Old Child Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy — Case Report and Review of Literature. Indian J Surg Oncol. 2021;12(Suppl 2):322-326. doi:10.1007/s13193-021-01351-3.

National Cancer Institute. Childhood Rhabdomyosarcoma Treatment (PDQ®)–Health Professional Version. Updated 2025. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/rhabdomyosarcoma-treatment-pdq.